Bellevue Asset Management (Switzerland)’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Bellevue Asset Management (Switzerland)’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	$74K	Hold	111	–	–	0.01%	125
2015 Q3	$53K	Sell	111 -56	-34%	-$29.7K	0.01%	131
2015 Q2	$95K	Buy	+167	New	+$462K	0.01%	137

Other funds holding EIGR

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

LOAMU

Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Bellevue Asset Management (Switzerland)'s EIGR Position: Q4 2015 in Review

Bellevue Asset Management (Switzerland) held its Eiger BioPharmaceuticals, Inc. (EIGR) position steady in Q4 2015 at 111 shares worth $74K. The position accounts for 0.01% of the portfolio, ranked #125.

Bellevue Asset Management (Switzerland) first reported a position in EIGR in Q2 2015 and has held it in 3 quarters since. The position peaked at $95K in Q2 2015. 41 funds tracked by Wall St. Rank hold EIGR as of Q4 2015.

Bellevue Asset Management (Switzerland) held 111 shares of Eiger BioPharmaceuticals, Inc. worth $74K as of Q4 2015.
Bellevue Asset Management (Switzerland) left its Eiger BioPharmaceuticals, Inc. share count unchanged in Q4 2015.
Eiger BioPharmaceuticals, Inc. made up 0.01% of Bellevue Asset Management (Switzerland)'s portfolio in Q4 2015, its #125 holding.
Bellevue Asset Management (Switzerland) first reported a position in Eiger BioPharmaceuticals, Inc. in Q2 2015 and has held it in 3 quarters since.
Bellevue Asset Management (Switzerland)'s Eiger BioPharmaceuticals, Inc. position peaked at $95K in Q2 2015.
41 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q4 2015.

Based on Bellevue Asset Management (Switzerland)'s 13F filing for Q4 2015, filed 12 Feb 2016.